Agata Raniszewska

Dr. Agata Raniszewska


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Cells
Verified
Journal Article
Open access
PDF file
ARAgata Raniszewska
Agata Raniszewska
Iwona KwiecieńIwona Kwiecień
Iwona Kwiecień
ERElżbieta Rutkowska
Elżbieta Rutkowska
JBJoanna Bednarek
Joanna Bednarek
RSRafal Sokolowski
Rafal Sokolowski
KJKarina Jahnz-Różyk
Karina Jahnz-Różyk
Although the role of T lymphocytes in sarcoidosis (SA) and lung cancer (LC) is quite well reported, the occurrence of B cells in disease microenvironments may suggest their potential role as natural modifiers of the immune response. The aim of this study was to investigate the B-cell profile and lymphocyte-related hematological parameters between patients with SA, LC and healthy controls (HCs). The cells were assessed by flow cytometry and a hematological analyzer in peripheral blood (PB) and material from lymph nodes (LNs) obtained by the EBUS/TBNA method. We showed that in SA patients, there were higher percentages of naïve B and CD21low B cells and a lower percentage of class-switched memory B cells than LC patients in LNs. We observed a higher median proportion of non-switched memory and transitional B cells in the PB of SA patients than in LC patients. We noticed the lowest median proportion of class-switched memory B cells in the PB from SA patients. LC patients had a higher percentage of RE-LYMP and AS-LYMP than SA patients. Our study presented a different profile of B-cell subpopulations in SA and LC patients, distinguishing dominant subpopulations, and showed the relocation from distant compartments of the circulation to the disease microenvironment, thus emphasizing their role.

27 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Iwona KwiecieńIwona Kwiecień
Iwona Kwiecień
ERElżbieta Rutkowska
Elżbieta Rutkowska
ARAgata Raniszewska
Agata Raniszewska
ARAgnieszka Rzeszotarska
Agnieszka Rzeszotarska
MPMałgorzata Polubiec-Kownacka
Małgorzata Polubiec-Kownacka
PRPiotr Rzepecki
Piotr Rzepecki
Macrophages play an important role in the suppression and activation of immune anti-cancer response, but little is known about dominant macrophage phenotype in the lung cancer environment, evaluated by bronchoalveolar lavage fluid (BALF). The aim of this study was to characterize macrophages in BALF from a lung affected by cancer (cBALF) and a healthy lung (hBALF) of the same patient regarding their individual macrophage polarization and selected cytokines profile. A total of 36 patients with confirmed lung cancer were investigated. Macrophages markers: CD206 CD163 CD80 CD86 CD40 CD45, Arginase-1, and CD68 were evaluated by flow cytometry. Cytokines (IL-1 RA, IL-6, IL-10, TNF-α, IL-1β, IL-12, IL-23, and TGF-β) profile was analyzed. There was higher median proportion of macrophages in Cbalf than in Hbalf. The population of macrophages presented immunophenotype: Ccd68+bright CD206+bright CD163+bright CD80+ CD86+ CD40+bright CD45+ cArginase+. We observed some trends in the expression of the analyzed antigens in clBALF and hlBLAF. The highest concentrations of IL-1RA and IL-6 were in Cbalf and Hbalf supernatant. There were the correlations between pro- and anti-inflammatory cytokines. The findings showed that macrophages include a diverse and plastic group with the presence of different antigens and cytokines, and determining the target phenotype is a complex and variable process.

26 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Iwona KwiecieńIwona Kwiecień
Iwona Kwiecień
ERElżbieta Rutkowska
Elżbieta Rutkowska
KGKrzysztof Gawronski
Krzysztof Gawronski
KKKatarzyna Kulik
Katarzyna Kulik
ADAlicja Dudzik
Alicja Dudzik
PRPiotr Rzepecki
Piotr Rzepecki
Myelodysplastic syndromes (MDS) are common malignant disorders with a poor prognosis. It is necessary to search for new rapid diagnostic methods to detect MDS patients with cytogenetic changes. The aim of the study was to assess new hematological neutrophil- and monocyte- related parameters I then bone marrow of MDS patient with and without cytogenetic changes. A total of 45 patients with MDS, including 17 patients with cytogenetic changes, were examined. The study was conducted using the Sysmex XN-Series hematological analyzer. New neutrophil and monocyte parameters, such as immature granulocytes (IG), neutrophil reactivity intensity (NEUT-RI), neutrophil granularity intensity (NEUT-GI), neutrophil size (NE-FSC) and neutrophil/monocyte data relating to granularity, activity and volume (NE-WX/MO-WX, NE-WY/MO-WY, NE-WZ/MO-WZ, MO-X, MO-Y, MO-Z) were evaluated. We observed higher median proportions of NE-WX, NE-WY, NE-WZ, and IG counts in MDS patients with cytogenetic changes than in patients without cytogenetic changes. The NE-FSC parameter was lower in MDS patients with cytogenetic changes than in patients without cytogenetic changes. The combination of new neutrophil parameters was found to be a new successful approach in distinguishing MDS patients with cytogenetic changes from patients without cytogenetic changes. It appears that there may be unique neutrophil parameter signatures associated with an underlying mutation.

4 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ERElżbieta Rutkowska
Elżbieta Rutkowska
Iwona KwiecieńIwona Kwiecień
Iwona Kwiecień
ARAgata Raniszewska
Agata Raniszewska
RSRafal Sokolowski
Rafal Sokolowski
JBJoanna Bednarek
Joanna Bednarek
PRPiotr Rzepecki
Piotr Rzepecki
The neutrophils evaluation seems interesting in the initial qualifications of patients with various inflammatory processes. In this study, we presented analysis of neutrophils and new parameters of the complexity (NEUT-GI, NE-WX), maturation (IG), size (NE-FSC, NE-WZ), and neutrophil activities (NEUT-RI, NE-WY) in coronavirus disease 2019 (COVID-19), lung cancer (LC), sarcoidosis (SA), and healthy controls (HCs). Peripheral blood (PB) was collected. The new parameters were examined by the Sysmex XN-1500. The mean absolute value for the IG parameter was the highest in the LC group. The differences in NEUT-RI value between COVID-19 and the HC group were observed. No significant differences were noticed between groups in the NEUT-GI granularity parameter. Neutrophil size assessed by NE-FSC parameter was reduced in all groups compared to HCs. The values of complexity (NE-WX), fluorescence (NE-WY), and size (NE-WZ) were the lowest in the HCs, whereas the highest median proportions of NE-WX, NE-WY, and NE-WZ were in LC patients. Patients from the SA group differed significantly from the HC group only for the NE-WZ parameter. We showed the usefulness of neutrophil parameters and their reactivity, morphology, and exhaustion. A more detailed analysis of blood counts may reveal trends that indicate a disease-specific immune response.

27 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Iwona KwiecieńIwona Kwiecień
Iwona Kwiecień
ERElżbieta Rutkowska
Elżbieta Rutkowska
ARAgata Raniszewska
Agata Raniszewska
RSRafal Sokolowski
Rafal Sokolowski
JBJoanna Bednarek
Joanna Bednarek
PRPiotr Rzepecki
Piotr Rzepecki
The presence of metastases in mediastinal lymph nodes (LNs) is essential for planning lung cancer treatment and assessing anticancer immune responses. The aim of the study was to assess LNs for the presence of neoplastic cells and evaluate lung cancer-selected antigen expression. LN aspirates were obtained during an EBUS/TBNA procedure. The cells were analyzed using a hematological analyzer and flow cytometry. It was possible to indicate the presence of cells characterized by high fluorescence connected with high metabolic activity using a hematological analyzer and to determine their non-hematopoietic origin using flow cytometry. Using these methods together, we detected very quickly a high proportion of cancer cells in LNs. We noticed that it was possible to determine a high expression of EpCAM, TTF-1, Ki67, cytokeratin, HER, and differences between non-small-cell (NSCLC) and small-cell lung cancer (SCLC) for the antigens MUC-1, CD56, HLA-DR, CD39, CD184, PD-L1, PD-L2 and CTLA-4 on tumor cells. We report, for the first time, that the detection of tumor cells in LNs with the expression of specific antigens is easy to evaluate using a hematological analyzer and flow cytometry in EBUS/TBNA samples. Such precise characteristics of non-hematopoietic cells in LNs may be of great diagnostic importance in the detection of micrometastases.

23 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KGKrzysztof Gawronski
Krzysztof Gawronski
NHNadia Hussein
Nadia Hussein
ERElżbieta Rutkowska
Elżbieta Rutkowska
Iwona KwiecieńIwona Kwiecień
Iwona Kwiecień
ARAgata Raniszewska
Agata Raniszewska
PRPiotr Rzepecki
Piotr Rzepecki
Background: This study aimed to analyze the survival of patients with multiple myeloma in relation to the value of endothelial cells involved in the process of tumor neoangiogenesis. Methods: In this non-randomized observational study, we prospectively evaluated a cohort of 74 adult patients with multiple myeloma who underwent a baseline assessment of the endothelial cell count in their bone marrow and received VCD or VTD anti-myeloma therapy followed by autoPBSCT. They were then evaluated for survival via long-term follow-up. Results: The survival of myeloma patients undergoing these therapies was analyzed, and we found that patients with higher endothelial cell counts had higher mortality rates during long-term follow-up. In the group of patients who died, the endothelial cell count was significantly higher (p = 0.024). We also observed that patients who initially had >2 osteolytic lesions had higher endothelial cell counts (p = 0.021). However, our analysis of endothelial cell count in relation to patient survival using antiangiogenic drugs showed that, in this group, the endothelial cell count was significantly higher in patients who died (p = 0.048). Conclusions: We found that patients with higher endothelial cell counts and those who did not receive antiangiogenic drugs from the start of therapy had higher mortality rates during long-term follow-up.